Erythrocyte aggregation is one of the important hemorheological factors which is related to pathogenesis of cerebral infarction. The purpose of the present study was to investigate the effect of ibudilast on erythrocyte aggregability (RBC-A) in patients with cerebral infarction. The subjects comprised 10 patients (6 males and 4 females, 62±5 years old ) with cerebral infarction during the chronic phase (more than 1 month after onset). Ibudilast (30 mg/day t. i. d.) was administered orally for 8 weeks to the patients. The RBC-A was measured using the whole blood RBC aggregometer developed by us (Am J Physiol 251: H1205-H1210, 1986) before, and 4 and 8 weeks after the ibudilast administration with concomitant measurement of blood factors such as hematocrit, albumin: globulin (A/G) ratio and fibrinogen concentration. The RBC-A values before, and 4 and 8 weeks after the ibudilast administration were 0.148±0.013/s, 0.139±0.020/s, and 0.134±0.017/s, respectively. The RBC-A values in 8 weeks after ibudilast administration was significantly (p<0.05) lower than that before ibudilast administration. The values of hematocrit, A/G ratio and fibrinogen concentration did not show any significant changes during 8 weeks. The above results indicate that ibudilast improves RBC-A in patients with cerebral infarction during the chronic phase.
抄録全体を表示